Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

FinlandBack to Finland

Clinical trials in Turku – page 25

300 clinical trials in Turku, Finland across 5 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

FinlandOur site in FinlandKliinisetTutkimukset.fi(opens in a new tab)
Turku at a glance
300
clinical trials
  • Research sites5
Type of trial
Recruitment status
Quick filters

300 trials in Turku

Open in trial search

Ovarian cancer recurrent

Not recruiting

Study of Pembrolizumab, Paclitaxel, and Bevacizumab for Patients with Platinum-Resistant Recurrent Ovarian Cancer

Registered drug
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:Anhydrous Docetaxel
  • Sponsor:Merck Sharp & Dohme LLC

Dementia Alzheimer's type

Not recruiting

Study on the Safety and Effects of BIIB080 for Patients Aged 50-80 with Mild Cognitive Impairment or Mild Alzheimer's Disease Dementia

Registered drug
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:Florbetaben (18F)
  • Sponsor:Biogen Idec Research Limited

Small cell lung cancer

Not recruiting

Study of MK-7684A, Etoposide, and Platinum Drugs for Patients with Extensive-Stage Small Cell Lung Cancer

Registered drug
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:Merck Sharp & Dohme LLC

Renal cell carcinoma

Not recruiting

Study of Pembrolizumab, Belzutifan, and Lenvatinib for Patients with Advanced Clear Cell Renal Cell Carcinoma

Registered drugNo placebo
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:Belzutifan
  • Sponsor:Merck Sharp & Dohme LLC

Non-small cell lung cancer

Not recruiting

Study of Belrestotug and Dostarlimab for Patients with Untreated Advanced Non-Small Cell Lung Cancer

Registered drug
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:Dostarlimab
  • Sponsor:Glaxosmithkline Research & Development Limited

Renal cancer metastatic

Not recruiting

Study on Cabozantinib, Nivolumab, and Ipilimumab for Patients with Advanced or Metastatic Kidney Cancer Who Have Not Received Prior Treatment

Registered drug
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:Cabozantinib
  • Sponsor:Exelixis Inc.

Hormone-refractory prostate cancer+1

Not recruiting

Study on Talazoparib and Enzalutamide for Patients with Metastatic Castration-Resistant Prostate Cancer

Registered drug
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:Enzalutamide
  • Sponsor:Pfizer Inc.

Plasma cell myeloma

Not recruiting

Study on the Effectiveness of Ixazomib, Lenalidomide, and Dexamethasone in Treating Newly Diagnosed Multiple Myeloma in Patients Eligible for Transplant

Registered drugNo placebo
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:Ixazomib
  • Sponsor:HUS-Yhtymae

Coronary artery disease

Not recruiting

Study on Ticagrelor and Acetylsalicylic Acid for Patients with Acute Coronary Syndrome Undergoing Coronary Artery Bypass Grafting

Registered drugNo placebo
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:Acetylsalicylic Acid
  • Sponsor:Vaestra Goetalandsregionen

Acute lymphocytic leukaemia

Not recruiting

Study on Imatinib and Chemotherapy Combination for Children with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Registered drugNo placebo
Countries:FinlandFinland
  • Participants:0–17 years · 18–64 years
  • Substances:Crisantaspase
  • Sponsor:Universita Degli Studi Di Milano Bicocca

Major depression

Not recruiting

Study on Aticaprant for Adults with Major Depressive Disorder and Anhedonia Not Responding to Antidepressants

Investigational
Countries:FinlandFinland
  • Participants:18–64 years
  • Substances:Aticaprant
  • Sponsor:Janssen Cilag International

Colon cancer+1

Not recruiting

Study on the Impact of DPYD Gene Test on the Safety and Efficacy of Fluorouracil, Capecitabine, and Tegafur in Finnish Patients with Breast or Colon Cancer

Registered drugNo placebo
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:HUS-Yhtymae

Other cities in Finland

The busiest research cities in the country

All 28 cities in Finland

Clinical research in Turku

What the registry says about research in the country

01 Respiratory Diseases

Comprehensive research focusing on respiratory infections including trials for influenza, RSV, and human metapneumovirus vaccines. Studies evaluate preventive measures for vulnerable populations.

  • Influenza vaccine development
  • RSV prevention in adults and infants
  • Viral respiratory infections

Multiple trials aim to enhance protection against seasonal respiratory illnesses in different age groups.

02 Infectious Diseases

Research centered on preventing and treating various infectious conditions, including studies of meningococcal vaccines and innovative approaches to viral infections.

  • Meningococcal prevention
  • Herpes Zoster vaccination
  • Yellow fever immunity

Studies focus on developing effective vaccination strategies for different age groups and populations.

03 Metabolic Disorders

Innovative trials examining treatments for obesity and diabetes, with particular attention to weight management therapies and metabolic health improvements.

  • Weight management interventions
  • Type 2 diabetes treatments
  • Combined therapeutic approaches

Research emphasizes lifestyle modifications alongside medical interventions.

04 Oncology

Advanced research in cancer treatment, particularly focusing on breast cancer and innovative therapeutic combinations for improved patient outcomes.

  • Breast cancer therapies
  • Leukemia treatments
  • Prostate cancer interventions

Studies evaluate both targeted therapies and combination treatments.

Back to FinlandAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.